Leukemia, Myelodysplasia, Transplantation
News
Gene signature may help guide initial CLL treatment choice
A 17-gene expression signature may help predict which patients with IGHV-unmutated disease will benefit from frontline FCR chemoimmunotherapy or...
News
Adverse cytogenetics trump molecular risk in NPM1-mutated AML
The findings have implications for postremission treatment decisions, including whether NPM1-mutated patients should receive allogeneic...
Conference Coverage
Targeted agents vs. chemoimmunotherapy as first-line treatment of CLL
SAN FRANCISCO – Experts debate the role of chemoimmunotherapy as first-line treatment of chronic lymphocytic leukemia.
News
Stem cells gene edited to be HIV resistant treat ALL, but not HIV
Conference Coverage
An Uncommon Complication of Chronic Myelomonocytic Leukemia: Acute Monocytic Transformation and Leukostasis
Conference Coverage
Severe Autoimmune Pancytopenia: An Unusual Presentation of Chronic Lymphocytic Leukemia (CLL)
News
Ibrutinib-venetoclax found highly active in hard-to-treat CLL
Trial results suggest the two drugs may have synergistic efficacy when used together, and raise the possibility of achieving MRD negativity with...
Conference Coverage
Ibrutinib tops chlorambucil against CLL
AMSTERDAM – The Bruton’s tyrosine kinase inhibitor was associated with a halving of risk for death, compared with chlorambucil.
Conference Coverage
For tough AML, half respond to selinexor plus chemotherapy
AMSTERDAM – The addition of selinexor looks promising in relapsed/refractory AML, but Karyopharm Therapeutics will be focusing first on approval...
Conference Coverage
Fixed-duration venetoclax-obinutuzumab superior to standard CLL therapy
CHICAGO – The immediately practice changing study offers a time-limited frontline option, one expert reported.